Safety concerns about Johnson & Johnson’s Covid-19 vaccine along with overall flagging demand for vaccinations have slowed its U.S. rollout to a crawl, leaving close to half of the 21 million doses produced for the United States sitting unused.
The U.S. Food and Drug Administration on May 19 authorized storage of Pfizer Inc. and German partner BioNTech SE’s Covid-19 vaccine at standard refrigerator temperatures for up to one month, in an effort to make the vaccine more widely available.
The World Health Organization (WHO) approved for emergency use a Covid-19 vaccine from China’s state-owned drugmaker Sinopharm on May 7, bolstering Beijing’s push for a bigger role in inoculating the world.
BioNTech is working on getting approval for a version of the company’s Covid-19 vaccine which can be stored in fridges of 2 to 8 degree celsius for up to 6 months, Chief Executive Ugur Sahin said on May 4.
India reported another record number of new Covid-19 infections on April 9 and daily deaths hit their highest in more than five months, as the country battles a second wave of infections and states complain of a persistent vaccine shortage.
The U.S. Food and Drug Administration on Feb. 25 approved storage and transportation of COVID-19 vaccine developed by Pfizer Inc. and German partner BioNTech SE at standard freezer temperatures for up to two weeks instead of ultra-cold conditions.
FDA to allow Pfizer-BioNTech vaccine to be stored at higher temps: NYT (Reuters) – The U.S. Food & Drug Administration plans to approve Pfizer Inc and BioNTech SE’s request to […]
Pfizer Inc. and BioNTech SE asked the U.S. health regulator to relax requirements for their Covid-19 vaccine to be stored at ultra-low temperatures, potentially allowing for it to be kept in pharmacy freezers.
Johnson & Johnson submitted data to the World Health Organization (WHO) for emergency use listing of the company’s Covid-19 vaccine, which would allow for wider access of the one-dose shot.